12-27-2012

Hyperosmolar therapy for raised intracranial pressure.

Ethan A Benardete
Thomas Jefferson University

Follow this and additional works at: <https://jdc.jefferson.edu/neurosurgeryfp>

Part of the [Neurology Commons](#)

[Let us know how access to this document benefits you](#)

Recommended Citation

Benardete, Ethan A, "Hyperosmolar therapy for raised intracranial pressure." (2012). *Department of Neurosurgery Faculty Papers*. Paper 22.

<https://jdc.jefferson.edu/neurosurgeryfp/22>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Neurosurgery Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

durable control of recurrent respiratory papillomatosis.^{4,5} Whether these pathways were also disrupted in the lung tumors of the patient described by Yuan and colleagues was not reported. Yuan et al. describe a cell-culture technique that was used to identify specific treatment for recurrent respiratory papillomatosis, but other agents may also be effective, and caution is advised before broadly using histone deacetylase inhibitors for recurrent respiratory papillomatosis.

Raj K. Batra, M.D.

Guy W. Soo Hoo, M.D., M.P.H.

Veterans Affairs Greater Los Angeles Healthcare System

Los Angeles, CA

guy.soo@va.gov

No potential conflict of interest relevant to this letter was reported.

1. Yuan H, Myers S, Wang J, et al. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. *N Engl J Med* 2012;367:1220-7.
2. Johnston D, Hall H, DiLorenzo TP, Steinberg BM. Elevation of the epidermal growth factor receptor and dependent signaling in human papillomavirus-infected laryngeal papillomas. *Cancer Res* 1999;59:968-74.
3. Wu R, Abramson AL, Shikowitz MJ, Dannenberg AJ, Steinberg BM. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. *Clin Cancer Res* 2005;11:6155-61.
4. Limsukon A, Susanto I, Soo Hoo GW, Dubinett SM, Batra RK. Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. *Chest* 2009;136:924-6.
5. Lucs AV, Wu R, Mullooly V, Abramson AL, Steinberg BM. Constitutive overexpression of the oncogene Rac1 in the airway of recurrent respiratory papillomatosis patients is a targetable host-susceptibility factor. *Mol Med* 2012;18:244-9.

DOI: 10.1056/NEJMc1212926

THE AUTHORS REPLY: Batra and Soo Hoo support our personalized cell technique that helped us to

identify a therapy for progressive recurrent respiratory papillomatosis. Although we found that vorinostat was cytotoxic in vitro and clinically effective in vivo, we agree with their comment that there may be additional therapeutic agents that our approach might be able to validate. Indeed, we are currently expanding our studies to explore such possibilities as well as applying our approach to nonviral neoplasia. However, we do not agree with their postulate that a “hit-and-run” mechanism was operative in the patient we described. Our polymerase-chain-reaction (PCR), reverse-transcriptase PCR, and cloning experiments indicate that wild-type and mutant HPV type 11 genomes were present in the laryngeal tumor and lung tumor, respectively. These findings are consistent with the well-documented role of HPV in virtually all cases of recurrent respiratory papillomatosis.¹⁻³

Hang Yuan, Ph.D.

Xuefeng Liu, M.D.

Richard Schlegel, M.D., Ph.D.

Georgetown University Medical Center

Washington, DC

schlegel@georgetown.edu

Since publication of their article, the authors report no further potential conflict of interest.

1. Smith EM, Pignatari SS, Gray SD, Haugen TH, Turek LP. Human papillomavirus infection in papillomas and nondiseased respiratory sites of patients with recurrent respiratory papillomatosis using the polymerase chain reaction. *Arch Otolaryngol Head Neck Surg* 1993;119:554-7.
2. Draganov P, Todorov S, Todorov I, Karchev T, Kalvatchev Z. Identification of HPV DNA in patients with juvenile-onset recurrent respiratory papillomatosis using SYBR Green realtime PCR. *Int J Pediatr Otorhinolaryngol* 2006;70:469-73.
3. Donne AJ, Hampson L, Homer JJ, Hampson IN. The role of HPV type in recurrent respiratory papillomatosis. *Int J Pediatr Otorhinolaryngol* 2010;74:7-14.

DOI: 10.1056/NEJMc1212926

Hyperosmolar Therapy for Raised Intracranial Pressure

TO THE EDITOR: Ropper (Aug. 23 issue)¹ recommends the use of mannitol at intervals of 2 to 4 or more hours to reduce intracranial pressure. Mannitol has been used for four decades to reduce intracranial pressure without solid evidence of benefit. In a randomized, controlled trial involving patients with intracerebral hemorrhage, mannitol improved neither the mortality nor the outcomes at 3 months.² Mannitol also did not improve cerebral blood flow as compared with saline in patients with intracerebral hemorrhage.³

In a study involving 6 patients with large hemispheric infarctions, mannitol boluses were associated with a clinically significant reduction of brain volume, which was most marked in the normal hemisphere.⁴ In another blinded study, mannitol administered in a 20% solution in boluses of 1.5 g per kilogram of body weight resulted in clinical improvement for 30 to 60 minutes in 5 of 12 patients with intracerebral hemorrhage, without a significant change in horizontal or vertical shift on magnetic resonance imaging.⁵ Fre-

quent and large doses of mannitol result in formation of idiogenic osmoles, leading to a reduction in efficacy and even to rebound brain edema. We therefore think that mannitol should be used cautiously in patients with raised intracranial pressure.

Usha K. Misra, M.D., D.M.

Jayantee Kalita, M.D., D.M.

Gourav Goyal, M.D., D.M.

Sanjay Gandhi Postgraduate Institute of Medical Sciences
Lucknow, India
drukmisra@rediffmail.com

No potential conflict of interest relevant to this letter was reported.

1. Ropper AH. Hyperosmolar therapy for raised intracranial pressure. *N Engl J Med* 2012;367:746-52.
2. Misra UK, Kalita J, Ranjan P, Mandal SK. Mannitol in intracerebral hemorrhage: a randomized controlled study. *J Neurol Sci* 2005;234:41-5.
3. Kalita J, Misra UK, Ranjan P, Pradhan PK, Das BK. Effect of mannitol on regional cerebral blood flow in patients with intracerebral hemorrhage. *J Neurol Sci* 2004;224:19-22.
4. Videen TO, Zazulia AR, Manno EM, et al. Mannitol bolus preferentially shrinks non-infarcted brain in patients with ischemic stroke. *Neurology* 2001;57:2120-2.
5. Misra UK, Kalita J, Vajpayee A, Phadke RV, Hadique A, Savlani V. Effect of single mannitol bolus in intracerebral hemorrhage. *Eur J Neurol* 2007;14:1118-23.

DOI: 10.1056/NEJMc1212351

TO THE EDITOR: Hypertonic saline has been associated with clinically significant renal insufficiency or acute renal failure in pediatric patients being treated for intracranial hypertension. In one study, 2 of 10 children being treated with mannitol and hypertonic saline for intracranial hypertension after traumatic brain injury required hemodialysis for renal failure.¹ In our study, we observed an increase in the serum creatinine level that was two to three times as high as the baseline level; this increase correlated with an increase in the serum sodium level above 160 mmol per liter (serum osmolality, >320 mOsm per liter) with the use of hypertonic saline (without mannitol) in pediatric patients with intracranial hypertension and maintenance of a euolemic hyperosmolar state.² As a result, our pediatric intensive care practitioners will attempt to avoid increasing the serum sodium level above 160 mmol per liter (serum osmolality, >320 mOsm per liter) when administering hypertonic saline for treating intracranial hypertension in pediatric patients.

Jimmy W. Huh, M.D.

Margaret A. Priestley, M.D.

University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Troy E. Dominguez, M.D.

Great Ormond Street Hospital
London, United Kingdom

No potential conflict of interest relevant to this letter was reported.

1. Khanna S, Davis D, Peterson B, et al. Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury. *Crit Care Med* 2000;28:1144-51.
2. Dominguez TE, Priestley MA, Huh JW. Caution should be exercised when maintaining a serum sodium level >160 meq/L. *Crit Care Med* 2004;32:1438-9.

DOI: 10.1056/NEJMc1212351

TO THE EDITOR: Ropper does not mention hyponatremic encephalopathy as a cause of raised intracranial pressure.¹ An equation for estimating the amount of hypertonic saline necessary to increase the serum sodium level is provided, and it is recommended that biochemical measurements (levels of serum sodium or serum osmolality, blood urea nitrogen, and serum creatinine) be checked every 8 hours. It is not mentioned that conditions associated with raised intracranial pressure are frequently associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and cerebral salt wasting.² Patients with SIADH and cerebral salt wasting can have hypertonic urine, with a combined urinary sodium and potassium concentration greater than that of plasma. The use of normal saline could actually result in a decrease in the serum sodium level, and the use of 3% saline could fail to raise the serum sodium level as much as calculated.³ A continuous infusion of both normal saline and 3% saline will probably be required to maintain hyperosmolality, and the serum sodium level should be checked at least every 4 hours.² A new class of drugs, vasopressin antagonists, may have a role in achieving and maintaining hyperosmolality in patients with raised intracranial pressure.⁴

Michael L. Moritz, M.D.

Children's Hospital of Pittsburgh
Pittsburgh, PA
michael.moritz@chp.edu

Juan C. Ayus, M.D.

Renal Consultants of Houston
Houston, TX

Drs. Moritz and Ayus report serving as consultants to Otsuka Pharmaceuticals. No other potential conflict of interest relevant to this letter was reported.

1. Moritz ML, Ayus JC. The pathophysiology and treatment of hyponatremic encephalopathy: an update. *Nephrol Dial Transplant* 2003;18:2486-91.
2. Moritz ML. Syndrome of inappropriate antidiuresis and cerebral salt wasting syndrome: are they different and does it matter? *Pediatr Nephrol* 2012;27:689-93.

3. Musch W, Decaux G. Treating the syndrome of inappropriate ADH secretion with isotonic saline. *QJM* 1998;91:749-53.
4. Galton C, Deem S, Yanez ND, et al. Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury. *Neurocrit Care* 2011;14:354-60.

DOI: 10.1056/NEJMc1212351

TO THE EDITOR: Important details regarding mannitol were omitted from Ropper's article regarding management of elevated intracranial pressure. Ropper asserts that mannitol causes an osmotic diuresis, therefore increasing the serum sodium concentration, which leads to water shifting out of the brain due to an osmotic gradient. The article suggests that kidney function is necessary for mannitol to reduce intracranial pressure. However, in our practice, my colleagues and I have used mannitol (0.25 to 1.0 g per kilogram of body weight intravenously) to control intracranial pressure in patients with anuric renal failure who are receiving long-term intermittent hemodialysis. In this clinical situation, we have observed rapid, sustained decreases in intracranial pressure with the administration of mannitol. It is likely that the action of mannitol is due to increased plasma osmolality after administration, causing water to shift out of the brain (for which renal function is not required).¹ Other possible mechanisms for the reduction of intracranial pressure associated with mannitol include an increase in cerebral perfusion,² causing cerebral vasoconstriction,³ and decreased production of cerebrospinal fluid.⁴ Other physicians may find, as we have, that the use of mannitol even in patients with chronic renal failure and elevated intracranial pressure is beneficial.

Ethan A. Benardete, M.D., Ph.D.

Thomas Jefferson University
Philadelphia, PA
ethan.benardete@jefferson.edu

No potential conflict of interest relevant to this letter was reported.

1. Winkler SR, Munoz-Ruiz L. Mechanism of action of mannitol. *Surg Neurol* 1995;43:59.
2. Rosner MJ, Coley I. Cerebral perfusion pressure: a hemodynamic mechanism of mannitol and the post-mannitol hemogram. *Neurosurgery* 1987;21:147-56.
3. Hartwell RC, Sutton LN. Mannitol, intracranial pressure, and vasogenic edema. *Neurosurgery* 1993;32:444-50.
4. Donato T, Shapira Y, Artru A, Powers K. Effect of mannitol on cerebrospinal fluid dynamics and brain tissue edema. *Anesth Analg* 1994;78:58-66.

DOI: 10.1056/NEJMc1212351

THE AUTHOR REPLIES: Misra and colleagues eschew the use of mannitol for raised intracranial pressure. This view may have merit, but they cite their own randomized trial¹ that involved approximately 60 patients, a third of whom had a cerebral hemorrhage smaller than 20 ml in volume and a third of whom had a cerebral hemorrhage larger than 40 ml in volume. As I discuss in my editorial² on the article by Chesnut et al.³ in this issue of the *Journal*, patients with small masses may not need treatment for intracranial pressure at all, and there may be a limited benefit to treating those with large lesions, so I am uncertain whether Misra's study settles the question of the usefulness of mannitol. If Misra and colleagues are questioning entirely the need to reduce intracranial pressure in cerebral hemorrhage, that is an interesting but separate polemic.

The risks of excessive dehydration in children are well noted by Huh and colleagues, and I commented in my article that serum sodium levels over 160 mmol per liter, arbitrarily stated by others to be the upper limit for safety, have been safely exceeded in adults.

Hyponatremic encephalopathy is an interesting entity, but in my experience it has not been obligatorily tied to brain swelling, especially when the cause is the natriuretic Nelson's syndrome. The other points made by Moritz and Ayus are worth noting, and vasopressin antagonists that cause hyperosmolality are a new prospect as treatment for raised intracranial pressure. An additional issue regarding the correction of hyponatremia is the risk of "osmotic demyelination" (formerly called "central pontine myelinolysis") if the level of sodium is made to rise too rapidly.

In response to the point made by Benardete about mannitol being effective even in patients with renal failure: my article indicates that a "sustained" reduction of intracranial pressure requires osmotic diuresis. I accept that the continued circulation of mannitol in patients with renal failure might allow a prolonged hyperosmolar effect until the sugar is metabolized, but repeat dosing would be required to sustain hyperosmolality, and chronic renal failure of a degree that prevents an osmotic diuresis is not typical in circumstances of raised intracranial pressure. Benardete is probably aware that the other oft-cited effects of mannitol on intracranial pres-

sure have been minor or transient in clinical studies.

Allan H. Ropper, M.D.

Brigham and Women's Hospital
Boston, MA

Since publication of his article, the author reports no further potential conflict of interest.

1. Misra UK, Kalita J, Ranjan P, Mandal SK. Mannitol in intracerebral hemorrhage: a randomized controlled study. *J Neurol Sci* 2005;234:41-5.
2. Ropper AH. Brain in a box. *N Engl J Med* 2012;367:2539-41.
3. Chesnut RM, Temkin N, Carney N, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. *N Engl J Med* 2012;367:2471-81.

DOI: 10.1056/NEJMc1212351

Missing Data in Clinical Trials

TO THE EDITOR: Little et al. (Oct. 4 issue)¹ mention limiting “the burden and inconvenience of data collection on the participants” as one of several ideas for limiting missing data in the conduct of clinical trials. Actually, this idea should be a design feature, and it is also important in limiting the burden on the investigator (a critical factor in successful data retrieval as well as patient accrual). Prominent trialists have long championed simple randomized trials for these and other reasons.² Simple, minimal data collection must be one of the most effective strategies for the prevention of missing data.

This concept is sometimes difficult to sell to investigators who may envision ancillary studies and additional publications ensuing from more data. However, quality trumps quantity, and perhaps this should be made clearer in criteria for academic promotion.

H. Daniel Lewis, Jr., M.D.

University of Kansas School of Medicine
Kansas City, KS
hdanlewis@earthlink.net

No potential conflict of interest relevant to this letter was reported.

1. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. *N Engl J Med* 2012; 367:1355-60.
2. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? *Stat Med* 1984;3:409-22.

DOI: 10.1056/NEJMc1213388

TO THE EDITOR: Little and colleagues correctly point out that missing data are often the result of study designs that mandate study discontinuation when treatment is discontinued.¹ Intention-to-treat inference based on randomization requires that patient data be collected regardless of treatment status. However, an issue requires further clarification. When following patients who are

off treatment, and methods are used to address data that are missing at random, the goal is to recreate a result that would have been obtained if patients who discontinued treatment had been followed after discontinuing treatment. The use of patients who are receiving treatment to impute the results for those who have discontinued treatment would seem to be problematic. In addition, if the common practice of no longer considering data on patients after treatment discontinuation is not altered, methods to address missing data that are based on statistical models will have no similar patients from whom to model the missing data. How do the authors suggest that we deal with this conundrum?

Joe Hirman, Ph.D.

Paul Flyer, Ph.D.

Pacific Northwest Statistical Consulting
Woodinville, WA
jhirman@pnwstat.com

No potential conflict of interest relevant to this letter was reported.

1. Flyer P, Hirman J. Missing data in confirmatory clinical trials. *J Biopharm Stat* 2009;19:969-79.

DOI: 10.1056/NEJMc1213388

THE AUTHORS REPLY: We agree with Lewis that limiting the burden on participants and investigators is important in the design of a study. Excessive data collection not only creates more opportunities for missing data, but it can distract attention from the collection of critical data. That said, covariate data, auxiliary data, and secondary-outcome data can serve valuable purposes, including improving the ability to understand and model the missing data.

Hirman and Flyer raise the important issue of the appropriate intention-to-treat analysis when patients go off the treatment protocol. We see three broad options, the relative usefulness of